Thus, the intratumoral delivery of HMGN1, the TLR7/8 agonist Resiquimod and checkpoint inhibitors cured established subcutaneous hepatomas and protected the mice against tumor rechallenge (see also TLR7/8) (77). Here, TLR7 is linked to hepatocellular carcinoma.